Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stellar Acquires Exclusive, Worldwide License to C. diff Immunotherapy Technology

Published: Wednesday, July 31, 2013
Last Updated: Wednesday, July 31, 2013
Bookmark and Share
Stellar expands with proprietary KLH-based vaccine program.

Stellar Biotechnologies, Inc. has announced that the Company has acquired the exclusive, worldwide license to patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”) from the University of Guelph (Ontario, Canada) (“Guelph”).

The license gives Stellar exclusive rights to develop, manufacture and sell human vaccines to treat C. diff infection that derive from technology covered by Guelph patents. The license also includes human diagnostic applications.

Specifically, the agreement covers a family of international patents and patent applications related to the cell-wall polysaccharide of C. diff named PSII.

“This opens significant new opportunities for Stellar and is an excellent fit in our goal to secure complementary technologies for strategic expansion,” said Frank Oakes, Stellar President and CEO.

Oakes continued, “We hold the world’s leading technology for sustainable manufacture of KLH protein and now we have a strong platform for Stellar’s first proprietary, active immunotherapy program.”

Herbert Chow, Ph.D., Stellar Chief Technology Officer said, “A PSII-KLH conjugate has the potential to be a major infectious disease immunotherapy, and we are concurrently proving the utility of Stellar KLH as a mucosal adjuvant in vaccines which opens the door for a multitude of new uses for Stellar KLH technology.”

Working under an option agreement executed last year, Stellar and Guelph scientists demonstrated in preclinical studies that conjugate vaccines combining PSII technology with Stellar’s KLH protein as adjuvant can protect against primary and secondary C. diff infection.

Last week, Stellar announced that results from the studies will be presented at the International ClostPath Conference this October.

University of Guelph professor Mario Monteiro, discoverer of the C. difficile Polysaccharide II, said, “Stellar’s vision has made it possible for our scientific discovery to migrate from the lab to the hands of industry. I’m confident that in time, this vaccine will prove to have saved many lives.”

“One of our goals at the University of Guelph is to move scientific discoveries out of the laboratories and put them to use to improve the quality of people’s health and daily lives,” said Kevin Hall, Guelph Vice-President Research. “There is no better way to do this than using academic expertise to help industry develop promising new applications that can have a positive impact globally.”

The agreement provides for Stellar to pay Guelph license fees in a combination of cash, stock and warrants, and milestone payments upon achievement of financing, development and sales targets.

Stellar will pay royalties on revenues and reimburse patent costs. Within 30 days of the effective date of the agreement and subject to TSX Venture Exchange approval, Guelph will receive 371,200 common shares and 278,400 warrants.

Each warrant provides Guelph the right to purchase one common share on or before January 24, 2015, at a purchase price of CDN$1.25 per share.

All securities issued under this agreement are subject to a hold period of four months and one day from the date of issuance.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stellar Signs Collaboration Agreement to Expand KLH Aquaculture Operations
Stellar secures strategic site in Mexico for exclusive sustainable KLH production.
Wednesday, August 12, 2015
Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Companies sign KLH supply agreement for Neovacs' Kinoid clinical trials and initial commercialization.
Saturday, April 04, 2015
Stellar and Araclon Biotech Sign Exclusive KLH Supply Agreement
Exclusive supply agreement for clinical trials in Alzheimer's active immunotherapies.
Wednesday, November 12, 2014
Stellar and Biovest Sign KLH Supply Agreement
Agreement for BiovaxID immunotherapy for follicular non-Hodgkin's lymphoma.
Tuesday, November 04, 2014
Stellar Biotechnologies Appoints Two Members to SAB
Appointment of Gregory T. Baxter and Charles V. Olson to the Company's Scientific Advisory Board.
Saturday, June 07, 2014
Stellar Biotechnologies Launches New Corporate Website
The new website showcases Stellar's Core KLH products, breakthroughs in aquaculture science, and strategic expansion of its immunotherapy program in a user-friendly platform.
Thursday, May 08, 2014
Stellar Issues Year-End Results and Highlights from 2013
Company announces financial results and operational highlights for 2013.
Friday, January 03, 2014
Stellar Announces Collaboration with Amaran Biotechnology, Inc.
Collaboration agreement to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy.
Friday, December 13, 2013
Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology
Issuance of two additional patents in U.S. and China.
Tuesday, December 10, 2013
Stellar Expands Senior Leadership Roles with Two Key Appointments
Appointment of Kathi Niffenegger and Catherine Brisson as CFO and COO respectively.
Wednesday, November 06, 2013
Stellar Presents Preclinical Poster on C. diff Active Immunotherapy
Poster presented at 7th Vaccine and ISV Congress being held in Spain.
Tuesday, October 29, 2013
Stellar’s Immunotherapy Technology Demonstrates Protection Against C. diff Infection
Study results presented this week at ClostPath 8 in Australia, October 22-26, 2013.
Tuesday, October 22, 2013
Stellar Appoints Tessie Che, Ph.D. to Board of Directors
Dr. Che is currently Chair of the Board of Directors of Amaran Biotechnology.
Thursday, September 26, 2013
Stellar Biotechnologies Exceeds Aquaculture Capacity Goals
Facility expansion and cultivation innovations ensure supply leadership.
Tuesday, July 23, 2013
Stellar Biotechnologies & Life Diagnostics Announce Agreement for Stellar Brand KLH ELISA Test Kits
Company to utilize Stellar’s high-quality KLH to develop and manufacture Stellar brand KLH ELISA test kits for the detection of anti-KLH antibodies.
Thursday, October 27, 2011
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!